CARDIOVASCULAR COMPLICATIONS AFTER KIDNEY TRANSPLANTATION
Complications After Kidney Transplantation, Akademisyen Kitabevi, ss.129-138, 2026
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2026
- Doi Numarası: 10.37609/akya.4215.c12418
- Yayınevi: Akademisyen Kitabevi
- Sayfa Sayıları: ss.129-138
- Anahtar Kelimeler: cardiovascular disease, coronary artery disease, heart failure, immunosuppressive therapy, kidney transplantation, post-transplant diabetes mellitus, post-transplant hypertension, risk stratification
- Çukurova Üniversitesi Adresli: Evet
Özet
Cardiovascular disease remains the leading cause of morbidity and mortality in kidney transplant recipients, accounting for 20–30% of all post-transplant deaths and arises from a multifactorial interaction between traditional risk factors — hypertension, dyslipidemia, diabetes mellitus, and smoking — and transplant-specific determinants including immunosuppressive drug toxicity, graft dysfunction, acute rejection, and prolonged pre-transplant dialysis. Immunosuppressive agents drive a distinct pathophysiological cascade — calcineurin inhibitors increase the risk of hypertension and dyslipidemia relative to tacrolimus, corticosteroids promote metabolic syndrome and post-transplant diabetes mellitus, and mTOR inhibitors exacerbate dyslipidemia via PCSK9 upregulation — collectively culminating in accelerated atherosclerosis, coronary artery disease, and de novo heart failure occurring in 10–18% of recipients within 36 months of transplantation. Addressing this burden demands a risk-stratified, multidisciplinary strategy that integrates pretransplant cardiac screening, guideline-directed blood pressure and lipid control, immunosuppression optimisation, and the judicious adoption of emerging cardiorenal therapies — and it is only through dedicated randomised trials in this population that the persistent evidence gap can be closed and the full promise of kidney transplantation realised.